Bal­loon­ing 340B mar­ket reach­es al­most 15% of 2021 US phar­ma sales, IQVIA finds

The tale of a boom­ing fed­er­al drug dis­count pro­gram, which phar­ma com­pa­nies have sought to cur­tail, has of­ten been told but rarely with new num­bers.

Now, the drug pric­ing gu­rus at IQVIA say their lat­est da­ta shows that the pro­gram, known as 340B and once de­signed to give mas­sive dis­counts to on­ly a se­lect num­ber of out­pa­tient drugs for on­ly a se­lect few health care providers, has bal­looned to $93.6 bil­lion in sales in 2021, which is about 15% of the to­tal $668.3 bil­lion in phar­ma sales for the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.